Key Insights

Highlights

Success Rate

91% trial completion (above average)

Published Results

15 trials with published results (9%)

Research Maturity

53 completed trials (32% of total)

Clinical Risk Assessment

Based on trial outcomes

Moderate Risk

Score: 40/100

Termination Rate

3.0%

5 terminated out of 168 trials

Success Rate

91.4%

+4.9% vs benchmark

Late-Stage Pipeline

19%

32 trials in Phase 3/4

Results Transparency

28%

15 of 53 completed with results

Key Signals

15 with results91% success

Data Visualizations

Phase Distribution

140Total
Not Applicable (59)
Early P 1 (1)
P 1 (13)
P 2 (35)
P 3 (21)
P 4 (11)

Trial Status

Recruiting53
Completed53
Not Yet Recruiting31
Active Not Recruiting9
Enrolling By Invitation7
Unknown7

Trial Success Rate

91.4%

Benchmark: 86.5%

Based on 53 completed trials

Clinical Trials (168)

Showing 20 of 20 trials
NCT07569198Phase 2Not Yet Recruiting

Ketamine With Dialectical Behavioural Therapy (DBT) for Suicidality in Individuals With Treatment-Resistant Depression and Borderline Personality Disorder (KET-DBT)

NCT06972368Not ApplicableRecruitingPrimary

Home-Based tDCS for Depression in BPD

NCT07571226Not Yet RecruitingPrimary

Identification and Molecular Characterisation of Urban-environmental Stress Patterns Affecting Mental Illness

NCT06922812Not ApplicableActive Not RecruitingPrimary

IWLS for Major Depressive Disorder: An Open-Label Study of Safety, Tolerability, and Efficacy

NCT06751875Not ApplicableCompletedPrimary

Preventing Relapse After Successful Electroconvulsive Therapy for Depression

NCT07396272Phase 2RecruitingPrimary

A Clinical Trial of Add-on Oral Slow-release Ketamine Treatment in Major Depression

NCT07539805Phase 2Not Yet RecruitingPrimary

Efficacy and Safety of Sertraline Combined With Lactobacillus Crispatus in Adolescents With Depression

NCT06624137Recruiting

Computer Game, Qualitative, and MEG/EEG Assessment of Serotonergic Psychedelics

NCT07300969Phase 2RecruitingPrimary

A Study to Evaluate the Effectiveness of DT-101 in Patients With Depression

NCT06793397Phase 3RecruitingPrimary

A Study of a Deuterated Psilocin Analog (CYB003) in Humans With Major Depressive Disorder

NCT07562191Phase 2Not Yet Recruiting

Inhaled DMT for Major Depressive Disorder

NCT07479758RecruitingPrimary

Biomarker Research on Ultra-High-Field MRI Combined With Visual Perception Assessment in the Diagnosis and Treatment Outcomes of Severe Mental Disorders

NCT06705270Not ApplicableNot Yet RecruitingPrimary

Sedation and Guided Education for Depression Study

NCT07549581Phase 1Completed

A Study of SEP-380135 in Adults With Schizophrenia or Major Depressive Episode

NCT07239843Enrolling By InvitationPrimary

Prospective Observational Study of the Relationship Between Sociodemographic Factors, Blood-based Biomarkers and Psychiatric Symptoms in Neurodegenerative Diseases and Mental Disorders

NCT06788249Early Phase 1RecruitingPrimary

Pilot Study: Establishing Glutamatergic Changes in Rapid Antidepressant Effects of Ketamine

NCT07284667Phase 2RecruitingPrimary

ACP-211 Monotherapy for Major Depressive Disorder With Inadequate Antidepressant Response

NCT06937476Not ApplicableActive Not RecruitingPrimary

Neurobiological Mechanisms of Pathological Rumination and Effects of Aripiprazole

NCT07533773Not ApplicableNot Yet RecruitingPrimary

Investigating Functional Changes in the Frontotemporal Cortex of Patients With Major Depressive Disorder Following Electroconvulsive Therapy or Magnetic Seizure Therapy Using Functional Near-infrared Spectroscopy (fNIRS)

NCT07529574Not ApplicableNot Yet RecruitingPrimary

Efficacy and Safety of a Theta Burst Stimulation Protocol of Repetitive Transcranial Magnetic Stimulation in Treatment-Resistant Depression

Scroll to load more

Research Network

Activity Timeline